Chronic Hives: Is Your Skin the Only Place That’s Inflamed?

By Doanh Nguyen, MD FAAAAI, 03/21/2026

For most people, hives are a temporary irritation, an itchy rash that appears during an allergic reaction and fades within hours or days. But for about one percent of the population, hives become something far more persistent. The condition, known as chronic spontaneous urticaria (CSU), causes recurrent outbreaks of raised, itchy welts or deeper swelling that can continue for months or even years.

The unpredictability of the disease can be debilitating. Patients often report waking up covered in hives without any obvious trigger. Work, sleep, and social life may all be disrupted by itching and swelling that seem to come and go at random.

Over the past decade, scientists have learned that chronic hives are not simply a skin problem. Instead, they reflect a complex immune disturbance involving inflammatory cells distributed throughout the body. Yet even as treatments have improved dramatically, a deeper question remains: could inflammation in other organs, particularly the lungs, help drive the disease in some patients?

A Disease of Mast Cells

At the center of chronic urticaria are mast cells, immune cells that reside in tissues exposed to the outside world, including the skin, lungs, and gastrointestinal tract. These cells act as early warning sentinels of the immune system. When mast cells detect danger, they release a burst of chemical signals such as histamine, leukotrienes, and cytokines. In the skin, this chemical cascade causes blood vessels to dilate and leak fluid into surrounding tissue. The result is the familiar raised, itchy welts known as hives.

In many cases of chronic urticaria, mast cells appear to be triggered not by environmental allergens but by the immune system itself. Research suggests that autoimmune processes are responsible for a substantial proportion of cases. Some patients produce antibodies that bind to their own IgE antibodies or to the receptors that control mast cell activation, effectively turning the immune system against itself.

This self directed activation helps explain why chronic urticaria often occurs without identifiable triggers and why it can persist for years.

The Modern Treatment Strategy

Despite its mysterious origins, the management of chronic urticaria has become increasingly systematic. Physicians typically begin with second-generation antihistamines, medications that block the effects of histamine in the skin. These drugs, such as cetirizine and fexofenadine, are far less sedating than older antihistamines and can be used safely on a daily basis. If symptoms persist, clinicians often increase the dose to improve effectiveness.

When antihistamines fail to provide adequate relief, physicians frequently prescribe omalizumab, a monoclonal antibody that neutralizes free IgE in the bloodstream. Originally developed for allergic asthma, this therapy has proven highly effective in chronic urticaria, with most patients experiencing substantial improvement. More recently, dupilumab, another biologic initially approved for asthma and atopic disease, has also shown benefit in patients with recalcitrant hives.

For the small group of individuals whose symptoms remain severe, doctors may turn to cyclosporine, a medication that suppresses immune pathways involved in mast cell activation. In addition, newer agents, such as remibrutinib, a Bruton’s tyrosine kinase inhibitor originally developed in oncology, are emerging as promising options in difficult to treat cases.

Together, these therapies enable the majority of patients to achieve meaningful control of their symptoms.

When Treatment Fails

Yet not all cases respond smoothly to the standard treatment ladder. Some patients continue to experience severe, persistent hives despite escalating therapy.

These difficult cases have prompted researchers to reconsider whether CSU might sometimes reflect a broader systemic inflammatory process rather than a purely cutaneous disorder. A small but intriguing clinical observation points toward the respiratory system as a possible contributor.

An Unexpected Clue from the Airways

In a recent case report published in the Journal of Medical Case Reports, clinicians at Texas Allergy Group described two patients with refractory chronic spontaneous urticaria, patients whose hives persisted despite conventional treatment. Further evaluation revealed that both individuals also had signs of inflammatory airway disease, including lower airway inflammation consistent with asthma or airway instability.

When physicians initiated treatment targeting the airway inflammation, the results were unexpected. As respiratory inflammation improved, the patients’ chronic hives also resolved, allowing reduction of other medications. Two cases cannot establish causation. But the observation raises an intriguing possibility: in some individuals, airway inflammation might amplify the systemic immune activity that triggers mast cells in the skin.

The Immune System as an Interconnected Network

From a biological standpoint, such a connection is not implausible. Mast cells are abundant not only in the skin but also in the airways and mucosal tissues. When activated in the lungs, they release many of the same inflammatory mediators that drive urticaria. These molecules can circulate throughout the body, potentially influencing immune responses in distant tissues.

This perspective reflects a growing recognition among immunologists that allergic diseases may represent interconnected manifestations of inflammation across multiple epithelial surfaces, the skin, lungs, sinuses, and gastrointestinal tract. Asthma, eczema, allergic rhinitis, and food allergies frequently cluster within the same individuals. Chronic urticaria may sometimes belong to this broader inflammatory landscape.

A Hypothesis Worth Exploring

For now, the relationship between airway inflammation and chronic urticaria remains a hypothesis rather than an established mechanism. Larger studies will be required to determine whether this connection applies to a meaningful proportion of patients.

But the possibility is scientifically intriguing. If airway inflammation contributes to systemic immune activation, addressing respiratory disease could potentially influence inflammatory conditions in other tissues.

Such an approach would represent a shift from viewing chronic urticaria as a localized skin disorder toward understanding it as part of a body wide immune network.

The Future of Chronic Urticaria Research

The treatment of chronic urticaria has already been transformed by advances in immunology, particularly the development of biologic therapies that target specific immune pathways. Researchers are now exploring additional treatments, including drugs that block intracellular signaling pathways involved in mast cell activation.

At the same time, emerging observations suggest that understanding the disease may require looking beyond the skin.

If future research confirms a connection between airway inflammation and chronic urticaria, it could open new avenues for diagnosis and treatment, highlighting once again how deeply interconnected the body’s immune defenses truly are.

For patients living with chronic hives, that broader perspective may ultimately offer a new path toward lasting relief.

Reference

1. Kocatürk E, Chu DK, Türk M, et al. Management of Chronic Spontaneous Urticaria Made Practical: What Every Clinician Should Know. J Allergy Clin Immunol Pract. 2025;13(9):2252-2269. doi:10.1016/j.jaip.2025.07.021

2. Nguyen D, Deitiker P. Sustained control of recalcitrant chronic spontaneous urticaria after initiation of inflammatory airway diseases treatment: two case reports. J Med Case Rep. 2024;18(1):113. Published 2024 Feb 23. doi:10.1186/s13256-024-04436-z

3. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090

4. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-1781.e1. doi:10.1016/j.jaci.2016.08.050

5. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-533. doi:10.1111/all.13083